BioStock: Annexin updates in conjunction with the Q3 report

In Annexin Pharmaceuticals’ third quarter report, focus is on the intensive work with the study within retinal vein occlusion, business development and continued investigation of expansion into other therapeutic areas. Going forward, the company will update on which additional area it intends to invest in with the candidate ANXV. BioStock reached out to CEO Anders Haegerstrand for a comment.

Read the full article about Annexin Pharmaceuticals at biostock.se:

https://www.biostock.se/en/2022/11/annexin-updates-in-conjunction-with-the-q3-report

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/